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Introduction
Progressive  supranuclear  palsy  (PSP),  also  known  as  Steele-Richardson-Olszewski 
syndrome, is a neurodegenerative disease that affects cognition, eye movements,  and 
posture . PSP was first described as a clinico pathologic entity in 1964. Characteristics 
include  supranuclear,  primarily  vertical,  gaze  dysfunction  accompanied  by  extra 
pyramidal symptoms and cognitive dysfunction. The disease usually develops after the 
sixth decade of life, and the diagnosis is purely clinical. 
The mean age at onset is  approximately 63 years,  with a range of 44-75 years .The 
median interval between onset and diagnosis is 3 years, with a range of 6 months to 9 
years
The  onset  of  PSP  is  insidious,  and  usually  a  prolonged  phase  of  vague  fatigue, 
headaches,  arthralgias,  dizziness,  and depression occurs.  Patients  also develop subtle 
personality  changes,  memory  problems,  and  pseudobulbar  symptoms,  and  family 
members are often a more accurate source of such information than the patient. The 
initial  symptoms  can  often  involve  unexplained  imbalance  or  falls.  Over  time, 
dysarthria, dysphagia, and visual symptoms ensue
The most common symptoms at disease onset were postural instability and falls (63%); 
dysarthria (35%); bradykinesia (13%); and visual disturbances such as diplopia, blurred 
vision, burning eyes, and light sensitivity (13%) .
The  cardinal  manifestations  of  PSP  are  supranuclear  ophthalmoplegia  pseudobulbar 
palsy;  prominent  neck  dystonia;  parkinsonism;  behavioral,  cognitive,  and  gait 
disturbances that cause imbalance; and frequent falls.
Although presentations vary and early  predominance of  a particular  symptom is  not 
unusual,  a  greater  spectrum of symptoms inevitably ensues over time.  Several  other 
features  have  been  reported,  including  sleep  disturbance  with  insomnia,  clumsiness, 
impaired  handwriting,  and  oscillopsia.  Although  the  full  constellation  of  symptoms 
occurring in a progressive fashion over time is characteristic, the vertical gaze palsy is 
the most distinctive single clinical feature.
Other features that can be prominent include focal or segmental dystonia in the form of 
limb dystonia or blepharospasm (Barclay, 1997).[ 1] 
Patients can also have asymmetric apraxia resembling corticobasal degeneration 
Clinical examination 
Slow vertical  saccades  and square  wave  jerks  are  early  signs  in  most  patients.  The 
classic gaze palsy in PSP is supranuclear ophthalmoplegia. Supranuclear in this context 
refers to a lesion above the ocular motor nuclei, thus sparing the ocular motor nuclei, 
nerve  fascicles,  and  neuromuscular  junctional  and extraocular  muscles.  Examination 
features serve to establish that the infranuclear structures are intact and that the lesion 
lies within the supranuclear domain. A supranuclear vertical gaze limitation is improved 
following extravolitional pathway activation, such as the vestibular ocular reflex (VOR) 
or the Bell phenomenon. 
The Bell phenomenon consists of upward eye deviation behind closed lids. This can be 
assessed clinically by partially holding the eyelid open and instructing the patient to try 
forcefully closing the eye. The vertical VOR can be activated by manually flexing and 
extending the neck while the patient views a distant target. If the extent of the vertical 
eye movement limitation is improved with either of these maneuvers, then the lesion is 
supranuclear in origin. 
Measurement of ocular alignment in the cardinal positions of gaze at near and distance 
viewing often discloses the source of any diplopic symptoms. 
Examination of the eyelid position and movements may yield critical information. 
The  characteristic  facies,  especially  when associated  with dysarthria,  may provide a 
nearly pathognomonic clinical picture
 The histopathology of PSP involves diffuse brainstem disease. Neuronal loss, NFTs, 
and gliosis affect the reticular formation and ocular motor nuclei. Early pathology is 
evident primarily in the mid brain, perhaps explaining the early vertical eye movement 
characteristics. The pontine nucleus raphe interpositus and pedunculopontine and deep 
pontine nuclei are also affected.
• The distribution and ultrastructure of NFTs in PSP is distinct from those found in 
Alzheimer disease. PSP is associated with more subcortical involvement, with 15- 
to 20-nm wide single tubules, compared to the cortically based paired helicoidal 
filaments of Alzheimer disease. 
• In  one  series,  examination  of  PSP  cases  revealed  the  uniform presence  of  t-
positive  cortical  lesions.  These  were  found  in  highest  concentration  in  the 
precentral  and angular  gyrus,  primarily  affecting  the  deep cortical  layers,  and 
involved both small and large neurons. These characteristics are distinct from the 
NFT pattern observed in Alzheimer disease. NFT concentration analysis appeared 
to implicate the pedunculopontine nucleus in lesion spread.
Although NFTs are the histologic hallmarks of PSP, neuropil threads have also been 
found extensively.
Besides the brainstem structures, the striatum, medial pallidum, subthalamic nucleus, 
and the substantia nigra are also affected.
The  clinical  diagnosis  of  Progressive  supranuclear  palsy,  particularly  its  differential 
diagnosis  with  Parkinson  disease  (PD),  can  be  difficult,  especially  in  early  stages  , 
However,  the   differential  diagnosis  between  Progressive  supranuclear  palsy   and 
Parkinson disease  is important, because the prognosis of Progressive supranuclear palsy 
is worse than that of Parkinson disease.
Clinical criteria 
Criteria for possible PSP are as follows: 
 Gradually  progressive  disorder  with  onset  when  the  individual  is 
aged 40 years or older 
 Either  vertical  supranuclear  palsy  or  both  slowing  of  vertical 
saccades and prominent postural instability with falls in the first year 
of onset 
 No evidence of other diseases that can explain the clinical features
Criteria for probable PSP are 
vertical supranuclear palsy with prominent postural instability, falls in the first year of 
onset, and other features of possible PSP, as follows: 
 Symmetric proximal greater than distal akinesia or rigidity 
 Abnormal neck posture, especially retrocollis 
 Poor or absent response of parkinsonism to levodopa therapy 
 Early dysphagia and dysarthria 
 Early cognitive impairment with at least 2 of the following: apathy, 
abstract  thought  impairment,  decreased  verbal  fluency,  imitation 
behavior, or frontal release sign
In the last 10 years, MR imaging investigations of Progressive supranuclear palsy  have 
shown  abnormalities  mainly  involving  the  midbrain;  such  changes  include  atrophy, 
abnormal T2 hyperintensity in the tegmentum, and narrowing of the substantia nigra . 
However,  the introduction of  MR imaging into  the routine workup of  patients  with 
suspected  Progressive  supranuclear  palsy   or  other  parkisonian  syndromes  has  been 
hampered by its low sensitivity and poor specificity and also by high variability, which 
can be heavily influenced by the neuroradiologist’s experience. 
Reports have shown that the quantitative evaluation of midbrain atrophy, based on its 
anteroposterior (AP) diameter calculation, is useful in the differential diagnosis
of  Progressive  supranuclear  palsy   and  Parkinson  disease,  because  it  is  more 
reproducible and less affected by reader experience
Aim of the study
To prospectively asses if AP Diameter of Midbrain , evaluated at MR imaging ,can help 
to differentiate Progressive supranuclear palsy from  Parkinson disease and whether it 
correlates with  age of the patient and  duration of disease
Review of literature
In 2001,MR imaging of midbrain diameter first done by Monica Warmuth-Metz et al 
[ 2]  in T2 W axial image to differentiate Progressive supranuclear palsy from Parkinson 
disease ,but  observed an important  overlap in  midbrain diameter  among Progressive 
supranuclear palsy and Multiple system atrophy patients 
In 2004,  Andrea Righini et al ,[ 3 ] performed,  MR imaging studies of 25 patients with 
Progressive supranuclear palsy and 27 with Parkinson disease were reviewed by means 
of  five  parameters:  midbrain  superior  profile  on  midsagittal  T1-weighted  images, 
midbrain  atrophy,  tegmental  abnormal  T2  hyperintensity,  abnormal  T2  putaminal 
hypointensity  or  hyperintensity  on  axial  proton  density–weighted  images.  We  also 
measured the anteroposterior diameter of the midbrain on axial T2-weighted sections at 
the level of the superior colliculus. observed The finding of an abnormal superior profile 
of the midbrain had 68% sensitivity and 88.8% specificity. Midbrain atrophy had 68% 
sensitivity and 77.7% specificity. 
TegmentalT2  hyperintensity  had  100%  specificity  but  poor  sensitivity  (28%).  Only 
14.8% of patients with PD and 24% of those with progressive supranuclear palsy had 
abnormal  putaminal  T2  hypointensity;  none  had  protondensity  hyperintensity.  With 
PSP, the average midbrain diameter was smaller than that with PD, but an important 
overlap was observed. Reader discordance was lower for the midbrain
superior profile sign (eight of 52 cases); this was similar for tegmental hyperintensity 
(nine of 52 cases) and higher for midbrain atrophy (16 of 52 cases).
In  2005  klaus  sepi  et  al   [  4  ]  observed  that  Magnetic  resonance  imaging-based 
volumetry  semi-automatic  segmentation  techniques  showed  volume loss  of  different 
supratentorial  and  infratentorial  brain  structures  in  patients  with  Multiple  System 
Atrophy (MSA ) and PSP .Patients with MSA showed significant reductions in mean 
striatal,  brainstem  and  cerebellar  volumes  ,  patients  with  PSP  showed  significant 
reductions  in  whole  brain,  striatal,  brainstem  –  especially  midbrain  –  and  frontal 
volumes
Magnetization transfer imaging MTI is based on the interactions between highly bound 
protons within structures such as myelin or cell membranes
and the very mobile protons of free water . By application of irradiation that selectively 
saturates the energy level of bound protons, exchange of magnetization
between bound and free protons is induced and the signal intensity of bound protons is 
reduced. The difference between signal intensities with and without
magnetization transfer is measured by calculating the magnetization transfer ratio, which 
correlates with the degree of myelinization and with axonal density
By using MTI in patients with neurodegenerative parkinsonian disorders, abnormalities 
of  the basal  ganglia  and substantia  nigra  were reported in  patients  with Parkinson’s 
disease, MSA and PSP . The most recent of these studies investigated the potential of 
MTI  in  the  differential  diagnosis  of  neurodegenerative  parkinsonism  including  37 
patients with different parkinsonian syndromes and 20 age-matched controls  The main 
finding in  this  study was a change in  the magnetization transfer  ratio in  the globus 
pallidus,  putamen,  caudate nucleus,  substantia nigra and white matter  in Parkinson’s 
disease,  MSA and PSP patients,matching the pathological  features of  the underlying 
disorder.  By  application  of  stepwise  discriminant  analysis,  there  was  a  good 
discrimination  of  Parkinson’s  disease  patients  and  controls  from the  MSA and PSP 
patients
DWI visualizes the random movement of the water molecules in the tissue by applying 
diffusion-sensitized gradients between two radio-frequency pulses [5]. The signal of the 
water molecules decreases with the extent of diffusion between the two radio-frequency 
pulses. An absolute quantification of the diffusivity is achieved by applying diffusion-
sensitized gradients of different degrees in three orthogonal directions and calculating 
the apparent diffusion coefficient (ADC) for each direction, which forms the trace of 
diffusion tensor  [6]. The central nervous system is highly organized in numerous tracts 
of myelinated fibre bundles, whereby the movement of the water molecules is restricted 
perpendicular to these fibre bundles. The resulting anisotropic diffusion is quantified by 
the fractional anisotropy, which is determined by diffusion-sensitized 372 Movement 
disorders  gradients  in  at  least  six  directions.  Both  the  diffusivity  and  the  fractional 
anisotropy form the diffusion tensor [5].
Pathological DWI findings in Parkinson’s disease patients are very rare.
In 2006 , Nicoletti et al [ 7 ] reviewed   Sixteen consecutive patients with MSA, 26 
consecutive  patients  with  PD,  and  14  healthy  control  subjects  examined  with  MR 
imaging, Images were interpreted independently by two experienced neuroradiologists 
blinded to clinical information, who visually inspected the images for the presence or 
absence  of  putaminal  atrophy,  putaminal  hypointensity,  slitlike  hyperintensity  in  the 
posterolateral margin of the putamen, brainstem atrophy, hyperintensity of the MCP, and 
cruciform hyperintensity  of  the  pons.  Measurements  of  MCP width on T1-weighted 
volumetric spoiled gradient-echo images were performed in all subjects. Differences in 
MCP  width  among  the  groups  were  evaluated  by  using  the  Kruskall-Wallis  test, 
followed  by  the  Mann-Whitney  U  test  for  multiple  comparisons  and  Bonferroni 
correction. All patients (mean age, 63.88 years; range, 55–72 years) with MSA had at 
least one of the features commonly observed in this disease on MR images, whereas 
control subjects (mean age, 66.93 years; range, 61–77 years) and all but one patient with 
PD (mean age, 65.31 years; range, 51–79 years) had normal MR images. The average 
MCP width was significantly smaller in patients with MSA (6.10 mm ± 1.18 [standard 
deviation]) than in those with PD (9.32 mm ± 0.77, P ≤.001) or control subjects (9.80 
mm ± 0.66, P ≤.001).
In 2007,quattronne et al  [ 8 ] reviewed , MRI of 21 patients with PSP, 23 patients with 
PD, 25 patients with MSA-P, and 31 age-matched normal control subjects. The areas of 
the midbrain tegmentum and the pons were measured on mid-sagittal MRI using the 
display tools of a workstation. The ratio of the area of the midbrain to the area of the 
pons was also evaluated in all subjects. The average midbrain area of the patients with 
PSP (56.0 mm2) was significantly smaller than that of the patients with PD (103.0 mm2) 
and MSA-P (97.2 mm2) and that of the age-matched control group (117.7 mm2). The 
values of the area of the midbrain showed no overlap between patients with PSP and 
patients with PD or normal control subjects.  However, patients with MSA-P showed 
some overlap of the values of individual areas with values from patients with PSP. The 
ratio of the area of the midbrain to the area of pons in the patients with PSP (0.124) was 
significantly  smaller  than that  in  those  with  PD (0.208)  and MSA-P (0.266)  and in 
normal control subjects (0.237). Use of the ratio allowed differentiation between the PSP 
group
Anatomy of midbrain
The  mid-brain or  mesencephalon  is the short, constricted portion which connects the 
pons and cerebellum with the thalamencephalon and cerebral hemispheres. It is directed 
upward and forward, and consists of (1) a ventrolateral portion, composed of a pair of 
cylindrical bodies, named the cerebral peduncles; (2) a dorsal portion, consisting of four 
rounded eminences, named the corpora quadrigemina; and (3) an intervening passage or 
tunnel, the cerebral aqueduct, which represents the original cavity of the mid-brain and 
connects the third with the fourth ventricle
The  cerebral  peduncles (pedunculus  cerebri;  crus  cerebri)  are  two cylindrical 
masses situated at the base of the brain, and largely hidden by the temporal lobes of the 
cerebrum, which must be drawn aside or removed in order to expose them. They emerge 
from the upper surface of the pons, one on either side of the middle line, and, diverging 
as  they  pass  upward  and  forward,  disappear  into  the  substance  of  the  cerebral 
hemispheres. The depressed area between the crura is termed the interpeduncular fossa, 
and consists of a layer of grayish substance, the posterior perforated substance, which is 
pierced by small apertures for the transmission of bloodvessels; its lower part lies on the 
ventral aspect of the medial portions of the tegmenta, and contains a nucleus named the 
interpeduncular  ganglion ,  its  upper  part  assists  in  forming  the  floor  of  the  third 
ventricle. The ventral surface of each peduncle is crossed from the medial to the lateral 
side by the superior cerebellar and posterior cerebral arteries; its lateral surface is in 
relation to the gyrus hippocampi of the cerebral hemisphere and is crossed from behind 
forward by the trochlear nerve. Close to the point of disappearance of the peduncle into 
the cerebral hemisphere, the optic tract winds forward around its ventro-lateral surface. 
The medial surface of the peduncle forms the lateral boundary of the interpeduncular 
fossa, and is marked by a longitudinal furrow, the  oculomotor sulcus, from which the 
roots of the oculomotor nerve emerge. On the lateral surface of each peduncle there is a 
second longitudinal furrow, termed the lateral sulcus; the fibers of the lateral lemniscus 
come to the surface in this sulcus, and pass backward and upward, to disappear under 
the inferior colliculus. 
T2 W Axial Image of  Superior Midbrain
  
Mid sagital MRI of Brain stem
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Structure of the Cerebral Peduncles, on transverse section, each peduncle is seen 
to consist of a dorsal and a ventral part, separated by a deeply pigmented lamina 
of  gray substance,  termed the  substantia nigra. The dorsal  part  is  named the 
tegmentum; the ventral, the base or crusta; the two bases are separated from each 
other, but the tegmenta are joined in the median plane by a forward prolongation 
of the raphé of the pons. Laterally, the tegmenta are free; dorsally, they blend 
with the corpora quadrigemina.
  The  base (basis pedunculi; crusta or pes) is semilunar on transverse section, 
and consists  almost  entirely  of  longitudinal  bundles of  efferent  fibers,  which 
arise from the cells of the cerebral cortex and are grouped into three principal 
sets, viz., cerebrospinal, frontopontine, and temporopontine. The  cerebrospinal 
fibers, derived from the cells of the motor area of the cerebral cortex, occupy the 
middle three-fifths of the base; they are continued partly to the nuclei of the 
motor cranial nerves, but mainly into the pyramids of the medulla oblongata. 
 Cerebral Aqueduct
Superior colliculus
Inferior colliculus
The  frontopontine fibers are situated in the medial fifth of the base; they arise 
from  the  cells  of  the  frontal  lobe  and  end  in  the  nuclei  of  the  pons.  The 
temporopontine fibers are lateral to the cerebrospinal fibers; they originate in the 
temporal lobe and end in the nuclei pontis.  
  The  substantia  nigra (intercalatum)  is  a  layer  of  gray  substance  containing 
numerous deeply pigmented, multipolar nerve cells. It is semilunar on transverse 
section, its concavity being directed toward the tegmentum; from its convexity, 
prolongations extend between the fibers of the base of the peduncle. Thicker 
medially  than  laterally,  it  reaches  from the  oculomotor  sulcus  to  the  lateral 
sulcus, and extends from the upper surface of the pons to the subthalamic region; 
its medial part is traversed by the fibers of the oculomotor nerve as these stream 
forward  to  reach the  oculomotor  sulcus.  The  connections  of  the  cells  of  the 
substantia nigra have not been definitely established. It receives collaterals from 
the medial lemniscus and the pyramidal bundles. Bechterew is of the opinion 
that the fibers from the motor area of the cerebral cortex form synapses with 
cells whose axons pass to the motor nucleus of the trigeminal nerve and serve 
for the coördination of the muscles of mastication.
  The  tegmentum is continuous below with the reticular formation of the pons, 
and,  like  it,  consists  of  longitudinal  and  transverse  fibers,  together  with  a 
considerable  amount  of  gray  substance.  The  principal  gray  masses  of  the 
tegmentum are the red nucleus and the interpeduncular ganglion; of its fibers the 
chief  longitudinal  tracts  are  the  superior  peduncle,  the  medial  longitudinal 
   
fasciculus, and the lemniscus.
  Gray  Substance.—The  red  nucleus is  situated  in  the  anterior  part  of  the 
tegmentum, and is continued upward into the posterior part of the subthalamic 
region. In sections at the level of the superior colliculus it appears as a circular 
mass which is traversed by the fibers of the oculomotor nerve. It receives many 
terminals and collaterals from the superior cerebellar peduncle also collaterals 
from the ventral  longitudinal  bundle,  from Gudden’s  bundle  and the median 
lemniscus. The axons of its larger cells cross the middle line and are continued 
downward into the lateral funiculus of the medulla spinalis as the rubrospinal 
tract ; those of its smaller cells end mainly in the thalamus. The rubrospinal tract 
forms an important part of the pathway from the cerebellum to the lower motor 
centers.
  The interpeduncular ganglion is a median collection of nerve cells situated in 
the ventral part of the tegmentum. The fibers of the fasciculus retroflexus of 
Meynert, which have their origin in the cells of the ganglion habenulæ ,end in it.
  From  the  lateral  aspect  of  each  colliculus  a  white  band,  termed  the 
brachium, is prolonged upward and forward. The superior brachium extends 
lateralward from the superior colliculus, and, passing between the pulvinar 
and medial geniculate body, is partly continued into an eminence called the 
lateral geniculate body, and partly into the optic tract. The inferior brachium 
passes forward and upward from the inferior colliculus and disappears under 
cover of the medial geniculate body.
 
  In  close  relationship  with  the  corpora  quadrigemina  are  the  superior 
peduncles, which emerge from the upper and medial parts of the cerebellar 
hemispheres. They run upward and forward, and, passing under the inferior 
colliculi, enter the tegmentum
   
 
Structure of the Corpora Quadrigemina.—The  inferior colliculus (colliculus 
inferior;  inferior  quadrigeminal  body;  postgemina)  consists  of  a  compact 
nucleus of gray substance containing large and small multipolar nerve cells, 
Imaging in Progressive Supranuclear Palsy
CT Brain
Most common finding observed in PSP is generalized cerebral atrophy, CT Brain shows 
reduction in AP diameter of Mid brain ( Midbrain Atrophy) but it is less sensitive and 
specific than MRI
MRI
MRI shows atrophy of the mid brain with cisternal and ventricular dilatation, thinning of 
the quadrigeminal  plate,  dilation of  the third ventricle,  and a  nonspecific  finding of 
increase in proton density images in the periaqueductal  gray matter compatible with 
gliotic changes Righini [ 3 ]reported the usefulness of midsagittal  T1-weighted MRI 
appearance of the superior profile of the midbrain; the appearance of a flat or concave 
profile (compared to the normal convex profile) was associated with a 68% sensitivity 
and an 89% specificity for the diagnosis of PSP compared to patients with Parkinson 
disease.  MR  shows  Mid  brain  atrophy  i.e.  reduced  anteroposterior  diameter  and 
hyperintensity in tegmentum
MR volumetry shows reduced volume of mid brain in PSP than PD
PET
These studies may help reveal physiopathologic aspects of the disease. PET studies have 
shown a global cerebral hypometabolism with relative selectivity in the frontal cortex , 
Regional cerebral blood flow and oxygen metabolism are decreased in the caudate and 
putamen and impaired in the thalamus and the brain stem.,lowered glucose metabolism 
in the midbrain compared to controls .Fluorodopa (F-dopa) PET has shown a reduction 
in the F-dopa influx in the caudate and putamen. 
SPECT
 Striatal  dopamine  receptor  binding  is  reduced  in  some  patients  with  PSP  with  I 
iodobenzamide SPECT
Materials and Methods
The study was performed on a 1.5 Tesla super conductive whole body MRI scanner 
SIEMENS MAGNETOM  SYMPHONY 
During the study the patient is placed on the strong homogenous magnetic field , the 
hydrogen nuclei  ,protons,  distributed through the entire  body tissue  generate  signals 
when stimulated by a radiofrequency pulse . these signals are processed in to images by 
a computer 
Study place
Barnard institute of radiology ,Madras Medical College
Study period
March  2007 to July 2008
Patient evaluation and selection 
Inclusion criteria 
Age > 40 yrs
Clinical diagnosis of idiopathic Parkinson disease and progressive supranuclear palsy
Normal CT brain 
Exclusion criteria 
Age < 40 yrs
Patients having organic cause for Parkinson disease and progressive supranuclear palsy
Patients with contraindication to MR
Data collection
All patients provided the informed consent for the study, brief history regarding the 
nature,duration and age at onset of the disease , history of truma, treatment history 
significant past and personal history  is taken from  all patients 
Base line CT brain was done 
Methods
All patients are examined with MRI , the studied parameters include AP diameter and 
superior profile of midbrain, mean middle cerebellar peduncle width ,tegmental  and 
putaminal intensity, differences In AP diameter of Midbrain among the groups were 
evaluated by using the Kruskall wallis test ,followed by Mann Whitney U test for 
bonferroni correction 
Sequence parameters 
T2 WI- axial(3500/85,4mm thickness)
FLAIR axial(8000/120/2000,4mm thickness)
T2*-axial(500/15/4mm thickness)
T1W SPGR sagital(15.2/6.8 thickness .72mm)
Interpretation
AP Diameter of midbrain measured  in T2 WI axial images at the level of red nucleus 
between interpeduncular fossa to quadrigeminal cistern in all patients and evaluated 
using Krus kall wallis test and  multiple comparison with Mann – whitney U test and 
bonferroni correction done
Superior profile of midbrain assessed  in T1 WI  mid sagital SPGR , convex profile is 
taken as normal , concave and flat profile is taken as abnormal i.e  finding suggestive of 
supranuclear palsy  , then the sensitivity and specificity  is assessed using statistical tests
 Middle cerebellar peduncle (MCP) width  measured in T1 WI  para sagital SPGR 
between superior and inferior cerebellar cistern  right and left MCP width is measured in 
all patients and average of the two is taken and evaluated using Krus kall wallis test and 
multiple comparison with Mann – whitney U test and bonferroni correction done
Tegmental  intensity in assessed T2 WI axial images , hyperintensity in the 
periaqueductal region is taken as finding suggestive of PSP ,then the sensitivity and 
specificity  is assessed using statistical tests
Results and Observation
The study was conducted in Twelve consecutive patients with PSP, 18  with PD referred 
from  neurology  department  ,  diagnosis  were  made  by  the  experienced  neurologist 
according to established criteria and  in 10 healthy control subjects, 
MEN/WOMEN 
The difference in sex distribution between patients with PSP , patients with PD, and 
control subjects was evaluated with the chi square test(p= 0.13)
Table 1- Sex Distribution
Groups Male Female
n % n %
p-value*
PSP 8 66.7 4 33.3
Parkinsons’ 14 77.8 4 22.2
Control 4 40.0 6 60.0
0.13
* Chi-square test
Age  at the time of study
There was no difference in age at the time of examination  (P= .570,ANOVA Test) 
between patients with PD (mean, 62.2years ± 7 [standard deviation];  and those with 
PSP(mean, 62years  ± 5.; and the control subjects (mean, 65years ± 7)
Table  2- Age  at the time of study
Groups Mean ± SD p-value*
PSP 62 ± 5
Parkinsons’ 62 ± 7
Control 65 ± 7
0.57
* ANOVA test
Mean Duration of disease
There was no difference in disease duration (P = .626) between patients with PD (mean, 
3.75 years) and those with PSP (mean, 3.25 years )
Table 3- Mean duration of disease
Groups Mean duration P value
PSP 3.25 years 0.62
PD 3.75 years
                                                    Age at onset
There was no difference in age at onset of disease( P =0 .848) between patients with PSP 
(mean, 58.75 years) and those with PD (mean, 58.5 years )
Table 4- Age at onset
Groups Age at onset P value
PSP 58.75 years 0.84
PD 58.5 years
Mid Brain AP Diameter
Table 5- Mid Brain AP Diameter
Groups Maximum 
AP(cm)
Minimum 
AP(cm)
Mean AP
(cm)
P value*
PSP 1.34 1.14 1.29 0.00
PD 1.58 1.82 1.70
CONTROL 1.65 1.81 1. 74
Mean MCP width
MCP width does not differ significantly among the groups (P= 0.54),PSP ( mean 
-0.99cm),PD(mean -0.97 cm) and control (mean-0.97 cm)
Table 6-Mean MCP width
Groups Maximum 
MCP(cm)
Minimum 
MCP(cm)
Mean MCP
(cm)
P value*
PSP 1.1 0.87 0.99 0.54
PD 1.05 0.89 0.97
CONTROL 1.06 0.88 0.97
*Anova test
AP Diameter of  Mid brain
AP diameter of midbrain measured in T 2 W axial images ( AP diameter < 15mm)
Has 100% sensitivity and specificity in differentiating PSP from PD and control 
Table  7 - Mid Brain AP Diameter
Groups Total no of patients No of patients having 
AP diameter < 15 mm
PSP 12 12
PD 18 0
CONTROL 10 0
Superior profile of midbrain
 Abnormal Superior profile of midbrain ( flat or concave profile) has 75 % sensitivity 
and 86% specificity in differentiating PSP from PD and control.
Table  8 - Superior profile of midbrain
Groups Total no of patients No of patients having 
Abnormal superior profile 
PSP 12 9
PD 18 3
CONTROL 10 1
Tegmental  hyper intensity
Tegmental  hyper intensity assessed in T2 W axial images  has 25 % sensitivity and 
100% specificity in differentiating PSP from PD and control.
Table  9 - Tegmental  hyper intensity
Groups Total no of patients No of patients having 
Tegmental  hyper intensity
PSP 12 3
PD 18 0
CONTROL 10 0
Age and AP diameter
Age and AP diameter of both PSP and PD groups were evaluated using spearmans co 
efficient (P> 0.05), there fore there is no correlation between Age and AP  diameter of 
midbrain in both groups  
Table  10 
- Age and 
AP 
Diameter
Disease Spearmans coefficient P value 
PSP 0.08 0.82 
PD 0.36 0.15 
Duration and AP diameter
 Duration  and AP diameter of both PSP and PD groups were evaluated using spearmans 
co efficient (P> 0.05), there fore there is no correlation between duration  and AP 
diameter of midbrain in both groups  
Table  11 - Duration and AP Diameter
AP Diameter of Mid brain
The mean anteroposterior midbrain diameter  significantly smaller in 
PSP( 1.29 cm ±0.06 cm ; ) than PD (1.70 cm ±0.08 cm) and control 1.74 cm  ±0.05 cm) 
P value = 0.001
Table  12- Mid Brain AP Diameter
Group Mean (SD) P value * 
PSP 1.29cm (0.06 cm) 0.001 
PD 1.70 cm (0.08 cm) 
CONTROL 1.74 cm  (0.05 cm) 
*-kruskall  wallis  test
Disease Spearmans coefficient P value 
PSP 0.43 0.16 
PD 0.16 0.52 
 Table 13- sensitivity and specificity of  parameters in differentiating PSP from PD 
and control groups 
AP DIA METER OF MID BRAIN
Parameter Sensitivity Specificity Positive 
predicitivity
Negative 
predictivity
Abnormal 
superior profile 
75% 86% 69% 89%
AP diameter of 
midbrain 
<15mm 
100% 100% 100% 100%
Tegmental 
hyperintensity 
25% 100% 100% 76%
Parkinson Disease
Progressive Supranuclear Palsy
Superior Profile of Midbrain
  Superior Profile of Midbrain  
Convex profile 
Flat Profile 
Concave  Profile 
MCP width
   Tegmental Hyperintensity
                                                              Discussion
MRI can be used to differentiate Progressive supranuclear Palsy from Parkinson disease 
Total  of  40 patients including 10 controls ,  twelve PSP  and Eighteen PD Patients 
formed the study group , most of the patients belong to 5th to 7th decade.
There is no statistically significant difference in men and women as (P= 0.13)  among 
the groups Chi-square test
Age at onset  ,mean duration of disease does not differ significantly among the groups
For diagnosis of  PSP
The AP diameter of Midbrain at the  level of Red nucleus between interpeduncular fossa 
to quadrigeminal cistern is measured in T2 W axial  images ,AP diameter less than 15 
mm is taken as positive finding i.e suggestive of progressive supranuclear palsy
Superior Profile of Midbrain assessed in Mid sagital T1 SPGR images convex profile is 
taken as Normal, Flat and Concave Profile is Taken as abnormal i.e 
A finding suggestive of PSP
Tegmental hyperintensity in T2 W axial images is also taken as finding suggestive of 
PSP
AP diameter of Midbrain in all PSP patients is less than 15 mm, but none of the PD and 
Control subjects .
The right and left Middle cerebellar Peduncle width measured in Parasagittal T1 w 
spoiled gradient echo images in all patients is greater than 8mm and does not differ 
significantly among the groups
Tegmental hyperintensity assessed in T2 w image is observed only 3 out of 12 patients 
with PSP and none of the PD and control group have tegmental hyperintensity , it is 
100% specific but has low sensitivity  of 25% only.
Superior profile of midbrain assessed in Mid sagital T1 w is abnormal ( flat or concave 
profile ) in 9 out of 12 patients, 3 out of 18 patients and one in control group has  75 % 
sensitive and 86 % specific in identifying PSP from PD and control group 
AP diameter of  Midbrain  measured in T 2 W axial images shows significant reduction 
in all PSP patients( < 15 mm), but none of the Parkinson disease and control patients 
have AP diameter less than 15 mm  evaluating with statistical tests 
It  has 100 % sensitivity  and Specificity  in differentiating PSP from PD and control 
patients
AP diameter of Midbrain also has 100 % positive and negative Predictive value 
In differentiating PSP from PD and Control group as there is no over lap in AP diameter 
among the PSP and PD groups
Superior Profile of Midbrain is less sensitive and specific than AP diameter of midbrain
Limitations
Limitation in our study , diagnosis is not validated with neuro pathology as none is 
proved by brain biopsy or autopsy after death
Clinical diagnosis may be in error, but the possibility of diagnostic error is unlikely as 
diagnosis were made according to  established criteria  by an experienced neurologist, 
and all patients had one of the finding commonly observed in PSP
And none of the PD and Control group had AP diameter of midbrain less than 15 mm in 
T2 W images
Conclusion
MR imaging  plays a major  role  in differentiation of  Parkinson and Parkinson Plus 
syndromes as it shows  excellent anatomic detail
There is no significant difference in Age at onset and  Mean duration of disease,   in PSP 
and PD groups
There is no sex predilection in all three groups 
Measurement of AP diameter of midbrain in T2 WI axial images at the level of Red 
nucleus between  interpeduncular fossa to quadrigeminal cistern  is simple, reliable and 
accurate method to differentiate  PSP from PD
AP Diameter  of  Midbrain less  than 15 mm in T2 W images is  100% sensitive and 
specific in differentiating PSP from PD 
None of the PSP patients have Mean MCP width less than 8mm ,A finding more in 
favour of MSA
There is no correlation between AP diameter and duration of disease and age of the 
patient  so  MR   imaging  help  us  to  reach  the  diagnosis  much  early  than  clinical 
examination 
Measurement of AP Diameter  of  Midbrain  in T2 W images can help to clinch the 
diagnosis of PSP in  patients with movement disorder
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Proforma
Name- 
Age /Sex- 
Address
Chief complaints 
Clinical finding 
1. Autonomic dysfunction
2. Cerebellar ataxia
3. Pyramidal signs
4. Gaze palsy
5. Pseudobulbar palsy
Duration of disease
Age at onset
Levodopa response 
MR  Findings 
Parameter PSP PD CONTROL
R MCP width
L MCP width
MEAN MCP Width
AP Diameter of Midbrain
Superior Profile of Midbrain
Tegmantal hyperintensity
Master Chart
PSP patients
PD  patients
Sno Age Sex Duration
(years)
Age 
at 
Onset
AP(cm) Sup 
profile
Tegmental 
hyperintensity
Mean 
MCPwidth
(cm)
1 65 male 3 62 1.76 normal - 1.025
2 82 female 15 67 1.69 normal - 1.015
3 61 male 2 59 1.68 normal - 0.925
4 57 male 2 55 1.62 normal - 0.965
Sno Age Sex Duration(years )
Age at 
Onset AP(cm)
Sup 
profile
Tegmenta
l hyper
Mean MCP 
width(cm)
1 70 male 4 66 1.34 abnormal + 0.97
2 69 female 3.5 65.5 1.31 abnormal - 1.03
3 54 male 2 52 1.14 abnormal - 0.87
4 61 male 6 55 1.32 abnormal - 0.99
5 64 female 5 59 1.29 abnormal - 1
6 59 female 2 57 1.3 normal - 0.96
7 58 male 4 54 1.22 abnormal + 1.04
8 64 male 3 61 1.26 abnormal - 0.89
9 60 male 2.5 57.5 1.27 abnormal - 0.98
10 56 female 1 55 1.36 normal - 1.02
11 62 male 2 60 1.32 normal - 1.1
12 67 male 4 63 1.38 abnormal + 1.07
5 58 male 1 57 1.67 normal - 0.98
6 60 male 1.5 58.5 1.68 normal - 1.015
7 68 male 7 61 1.62 normal - 0.94
8 63 male 3 60 1.72 abnormal - 0.94
9 64 male 2 62 1.63 normal - 0.99
10 62 male 4 58 1.76 normal - 0.96
11 70 male 5 65 1.81 normal - 0.91
12 63 male 3 60 1.68 normal - 0.89
13 66 male 2 64 1.82 normal - 0.92
14 55 male 4 51 1.76 normal - 0.98
15 60 female 3 57 1.58 abnormal - 0.99
16 54 male 5 49 1.82 abnormal - 1.045
17 54 female 2 52 1.59 normal - 1
18 58 female 3 55 1.77 normal - 0.99
Control patients 
S.no Age Sex AP(cm) Sup profile Tegmental hyperintensity
Mean MCP 
width (cm)
1 58 male 1.74 normal - 1.06
2 67 female 1.79 normal - 0.98
3 59 female 1.74 normal - 0.94
4 76 female 1.71 normal - 1.01
5 55 male 1.76 normal - 1.03
6 72 female 1.69 normal - 0.96
7 59 male 1.77 normal - 0.99
8 64 female 1.81 abnormal - 1
9 71 female 1.65 normal - 0.89
10 64 male 1.7 normal - 0.92
Glossary 
MR------  Magnetic Resonance
AP-------  Anteroposterior
PSP-----  Progressive Supranuclear Palsy
PD ------ Parkinson Disease
MSA---- Multiple System Atrophy
MCP--- Middle Cerebellar Peduncle 
